Navigation Links
Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
Date:3/9/2010

CMX001 is a new chemical entity created by applying Chimerix's PIM (Phospholipid Intramembrane Microfluidization) conjugation technology to chemically modify cidofovir, an approved antiviral agent requiring intravenous administration, to produce a highly potent and well-tolerated oral antiviral with broad-spectrum activity.

The enhanced antiviral activity of CMX001 has been characterized in both in vitro and in vivo studies.  In clinical testing to date, CMX001 has shown oral bioavailability in humans and has demonstrated a positive safety profile.  In cell culture assays, CMX001 is significantly more active than cidofovir against numerous dsDNA families of viruses including orthopoxviruses, herpesviruses and multiple adenoviruses.  CMX001 is initially being developed for both commercial and medical preparedness uses.  In addition to the Phase 2 clinical trial in stem cell transplant recipients, Chimerix is conducting a multi-dose Phase 1 clinical trial of CMX001 in transplant recipients with BK viruria, which like CMV can cause serious complications in immunocompromised patients.

About Chimerix

Chimerix is developing antiviral therapeutics to treat life-threatening diseases.  Le
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
2. Chimerix to Present at Two Upcoming Investor Conferences
3. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
4. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
5. ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
6. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
9. Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui
10. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
11. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... DIEGO , Oct. 20, 2014  AnaptysBio, ... of therapeutic antibodies, today announced the appointment of ... Officer. Dr. Londei will lead the preclinical and ... "We are pleased to welcome Dr. ... Hamza Suria , President and Chief Executive Officer ...
(Date:10/20/2014)... 20, 2014 Pharmaceutic Labs announces the opening ... Albany, NY for admixing, compounding, drug ... and/or exceeds the FDA standards for safety and quality, ... 211. The 10,000 square foot outsourcing ... quality assurance and quality control. The company will produce ...
(Date:10/20/2014)... and RALEIGH, N.C., Oct. 20, 2014  BioPontis Alliance ... (HNF), both philanthropies, announced today the creation of ... the treatment of the rare disease known as ... announced its alliance model earlier this month. Today,s ... of a collaborative model where researchers and all ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3
... , THE WOODLANDS, Texas , Jan. ... that it is changing its name to the Life Beyond Cancer ... the organization aspires to provide to cancer patients and their families. ... local communities by removing barriers to prevention, education, early detection, treatment ...
... , JERUSALEM , ... biopharma company, announced today that it has granted Novartis an option ... Transient Permeability Enhancer (TPE) technology for use with certain related small ... In a separate but related agreement, the MPM Bio IV NVS ...
Cached Medicine Technology:US Oncology Foundation Becomes Life Beyond Cancer Foundation 2US Oncology Foundation Becomes Life Beyond Cancer Foundation 3Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products 2Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products 3
(Date:10/20/2014)... 2014 Unveiled at the Sept. 18 board ... conservatively estimates member hospital ROI on membership dues at 12.5. ... Center provides $12.50 in value to member hospitals. The calculation ... Member Dues)/Member Dues. , “This is the first time ... we think the methodology is really sound,” said Bill ...
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
(Date:10/19/2014)... York (PRWEB) October 19, 2014 Dr. ... Population Fund, welcomes news of a ceasefire agreement that ... more than 200 girls who were kidnapped from the ... have languished in captivity long enough, and it is ... and communities," stated Dr. Osotimehin. , "We owe it ...
(Date:10/19/2014)... Fancyflyingfox.com, an innovative company that provides many kinds of ... of 2014 mother of the bride dresses . ... with big discounts, up to 70% off. All consumers ... this special offer. , Owing to the company’s ... of the leading brands in the global market. A ...
(Date:10/19/2014)... (HealthDay News) -- New stem cell-based research could improve ... treatments, a new study suggests. Scientists used stem ... in a lab dish. They then transplanted the organoids ... disorders, according to the researchers. "This provides a ... that can cause intestinal failure, from genetic disorders appearing ...
Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2
... the Bench,-, EL SEGUNDO, Calif., Oct. 16 ... solutions for microarray-based,research, announced today the release of ... that provides easy, fast and powerful platform,independent and ... data sets, simultaneously. NEXUS CGH easily supports ...
... The department of bioengineering at Clemson University has received ... Both the National Institutes of Health (NIH) and a ... (NSBRI www.nsbri.org ), are primary contributors of funds ... application. , The study addresses bone loss that occurs ...
... YORK, Oct. 16 Even though Americans pick up ... toothbrushes,may need a cleaning of their own. Celebrity Dentist ... says a new survey conducted by the,Philips Sonicare brand ... Listen to this report from Philips (NYSE: ...
... Unique Request Highlights December 2 Annual Wells Fargo Walk of Ages ... ... Home is,inviting everyone with the name of "Walker" in the United States to ... Walk of,Ages" on December 2 in Reseda. According to official census records there,are ...
... - BCL.P, VANCOUVER, Oct. 16 /PRNewswire-FirstCall/ ... announce that it has entered into an ... (the "Arrangement,Agreement") with iCo Therapeutics Inc. ("iCo"). ... constitute Beanstalk,s,"Qualifying Transaction" as a capital pool ...
... children appear to have a lower risk of asthma ... a non-agricultural rural environment, according to a University of ... 13,524 asthmafree children aged less than 12 years in ... Youth (NLSCY) showed that children living in a farming ...
Cached Medicine News:Health News:BioDiscovery Releases NEXUS CGH Version 2 for DNA Copy Number Analysis and Visualization 2Health News:Clemson awarded $2M to study radiation-induced bone loss 2Health News:FORGET THE JONESES, This is All About Keeping up With the Walkers as the Los Angeles Jewish Home Sends Out an Invite to Everyone Named 'Walker' in the United States 2Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 2Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 3Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 4Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 5Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 6Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 7Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 8Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 9Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 10Health News:Farm kids have lower risk of asthma, study shows 2
Double Ended Occluders...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Long handle occluders are approximately 9 inches long....
Long handle occluders are approximately 9 inches long....
Medicine Products: